This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.
Original paper

SGLT-2 Inhibitors and Cardiovascular Risk

Volume: 71, Issue: 22, Pages: 2497 - 2506
Published: May 28, 2018
Abstract
Prior studies found patients treated with sodium-glucose co-transporter-2 inhibitors (SGLT-2i) had lower rates of death and heart failure (HF). Whether the benefits of SGLT-2i vary based upon the presence of cardiovascular disease (CVD) is unknown. This study sought to determine the association between initiation of SGLT-2i therapy and HF or death in patients with and without CVD. The CVD-REAL (Comparative Effectiveness of Cardiovascular...
Paper Details
Title
SGLT-2 Inhibitors and Cardiovascular Risk
Published Date
May 28, 2018
Volume
71
Issue
22
Pages
2497 - 2506
© 2025 Pluto Labs All rights reserved.
Step 1. Scroll down for details & analytics related to the paper.
Discover a range of citation analytics, paper references, a list of cited papers, and more.